---
schema_version: "secwatch.filing_event.v1"
accession: "0001285550-23-000114"
form_type: "8-K"
ticker: "CLPT"
cik: "0001285550"
company_name: "ClearPoint Neuro, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:08:26.519905+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ClearPoint Neuro Q3 revenue $5.8M (+12% YoY); biologics & drug delivery up 55% to $3.5M

## Summary
- Revenue $5.8M, +12% YoY; biologics & drug delivery $3.5M (+55%) driven by preclinical services.
- Gross margin 57% vs 71% prior year due to lower-margin preclinical services and facility transition.
- Operational cash burn $1.8M, lowest since 2020; cash $24.3M at Sept 30.
- FY 2023 revenue guidance narrowed to $23-25M, representing 11-18% growth.
- Entered new strategic biologics agreements; submitted three stereotactic products and updated software to FDA.

## SEC filing metadata
- accession: 0001285550-23-000114
- form_type: 8-K
- ticker: CLPT
- cik: 0001285550
- company_name: ClearPoint Neuro, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285550/000128555023000114/0001285550-23-000114-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285550/000128555023000114/clpt-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001285550-23-000114
- JSON: https://secwatch.observer/filing/0001285550-23-000114.json
- Plain text: https://secwatch.observer/filing/0001285550-23-000114.txt

## Key facts
- Earnings Releases
  ClearPoint Neuro, Inc. reported third quarter ended September 30, 2023 results: revenue $5.8 million, net income ($0.34) per diluted share, EPS ($0.34) per diluted share. Guidance reaffirmed.
  - Period: third quarter ended September 30, 2023
  - Revenue: $5.8 million
  - Net income: ($0.34) per diluted share
  - EPS: ($0.34) per diluted share
  - Guidance: reaffirmed
  - Result: reported results
  source text: navigation and delivery to the brain, today announced financial results for its third quarter ended September 30, 2023. Third Quarter Highlights • Reported quarterly revenue of $5.8 million, a 12% year-over-year increase; • Increased biologics and drug delivery revenue to $3.5 million, a 55% year-over-year increase; • Operational cash burn of $1.8 million, the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1285550/000128555023000114/0001285550-23-000114-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.